

AR FY25: Diversification aids growth, consumer connect

Consumer Goods ▶ Company Update ▶ August 03, 2025

CMP (Rs): 710 | TP (Rs): 810

We maintain BUY with Jun-26E TP of Rs810, on 50x P/E. We see improved execution ahead helping in driving growth and better margins which would enable the company to see ~12% earnings CAGR over FY25-28E. The new portfolio (1/4th of consolidated revenue) in India and internationally is aligning with consumer needs, enhancing longevity of growth. In India, the new-age portfolio in food and digital brands accounts for 22% of revenue. Internationally, Marico has created a premium portfolio, which represents 29% of sales. We see execution in this portfolio being key for its aspiration to double revenue by 2030 (~15% CAGR). In FY25, the company's earnings grew by 10% which helped with a better dividend and return profile (ROE ~42%, +3ppt YoY), although higher working capital needs kept the OCF flat YoY.

Aspiring to double revenue by 2030 by strengthening growth construct

Having crossed the Rs100bn milestone in FY25, the company now aims to double revenue over the next 5Y. The focus remains on outperforming core categories, gaining market share, and scaling up emerging businesses profitably. In India, the management sees tailwinds in rural and opportunities among the youth (where D2C brands are reshaping the FMCG ecosystem). Ahead, Marico would maintain its thrust on execution around new-age consumers, where needs are evolving fast. In FY25, the company's new growth engine in India (combined ARR of Rs20bn) was sized at Rs9bn in food, Rs3bn in premium personal care, and Rs6bn in the digital-first portfolio. Amid digital brands, Plix is now the biggest with revenue of Rs4.3bn (grew 179% YoY; holds the potential to reach Rs10bn in the medium term), followed by Beardo at Rs2.1bn (grew 24% YoY; medium-term potential at Rs5bn). The company maintains its focus on general trade (5.8mn outlets; under Project SETU, it aspires to expand its current 1mn direct reach to 1.5mn outlets by FY27). Internationally, its focus is on innovation and expansion in premium personal care categories, which now account for 29% of international revenue.

Coconut oil revenue concentration influences profitability

Marico's sizable revenue (1/3rd in India and ~3/5th in Bangladesh) is concentrated in the coconut oil segment, which now accounts for 31% of revenue. With a focus on diversification, it has reduced category dependence by ~5ppt in the last five years. This diversification is reflected in relatively better gross margin management in the current inflationary cycle. We see steady revenue diversification ahead which will arrest margin volatility. Copra, a key raw material, has seen a sharp surge in prices in the last 6M across India and Indonesia. Recent trends suggest easing in copra prices, with price deflation accelerating on improvement in seasonal supplies. We believe the initial thrust should be on maintaining the current price premium; as copra prices reach comfort zone, the company should focus on recouping the price premium.

Valuation aligns with 5YF average; re-rating likely on enhanced execution

We like Marico, given its attentiveness to align the business with evolving consumer needs. Its current valuation (FY27E P/E at 43x) aligns with the 5YF average P/E which is likely to expand on better delivery ahead. We maintain BUY with a TP of Rs810.

Target Price – 12M	Jun-26
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	14.1

Stock Data	MRCO IN
52-week High (Rs)	745
52-week Low (Rs)	578
Shares outstanding (mn)	1,297.8
Market-cap (Rs bn)	921
Market-cap (USD mn)	10,527
Net-debt, FY26E (Rs mn)	(9,584.6)
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	1,627.8
ADTV-3M (USD mn)	18.6
Free float (%)	40.8
Nifty-50	24,565.3
INR/USD	87.5

Shareholding, Jun-25

Promoters (%)	59.0
FPIs/MFs (%)	23.6/12.7

Price Performance

(%)	1M	3M	12M
Absolute	(1.0)	(0.1)	5.2
Rel. to Nifty	2.9	(1.0)	7.1

1-Year share price trend (Rs)**Marico: Financial Snapshot (Consolidated)**

Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	96,530	108,310	122,640	133,780	147,024
EBITDA	20,260	21,390	23,737	27,876	30,704
Adj. PAT	14,810	16,290	17,717	20,698	22,714
Adj. EPS (Rs)	11.5	12.6	13.7	16.0	17.6
EBITDA margin (%)	21.0	19.7	19.4	20.8	20.9
EBITDA growth (%)	11.9	5.6	11.0	17.4	10.1
Adj. EPS growth (%)	13.7	10.0	8.8	16.8	9.7
RoE (%)	38.8	41.7	43.0	46.8	47.7
RoIC (%)	55.5	51.2	54.9	62.3	65.9
P/E (x)	61.8	56.2	51.7	44.2	40.3
EV/EBITDA (x)	44.9	42.5	38.3	32.6	29.6
P/B (x)	23.9	23.0	20.9	18.6	17.0
FCFF yield (%)	1.3	1.4	1.8	2.1	2.3

Source: Company, Emkay Research

Nitin Gupta
 nitin.gupta@emkayglobal.com
 +91-22-66121257

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

Targets to double revenue by 2030

Aspires to be a globally admired digital FMCG company

As the company attained the revenue milestone of Rs100bn in FY25, the management's thrust is to double revenue in the next five years. It has a clear roadmap in place rooted in innovation, purposeful brand-building, and operational excellence. The management's thrust remains on a) outperforming the category and gaining share in core portfolios and b) profitable scale-up of emerging businesses. The company will have strategic investments and a commitment to building scalable, resilient businesses; it has cultivated a vibrant new-age digital-first portfolio that is progressively stepping up its contribution to both the topline and bottomline each year.

Focus on 4Ds: Diversification, Distribution, Digital, and Diversity

The management's thrust is on driving the 4Ds to deliver sustainable and profitable growth – Diversification, Distribution, Digital, and Diversity.

- **Diversification:** In India, the company has made steady progress in diversification with thrust on food and premium personal care, which now contributes 22% to revenue vs 11% in FY22. The management's endeavor is to expand the contribution to 25% by FY27. Notably, the rapid scale-up in these portfolios was accompanied by an improvement in their margin profiles, thus reflected in their share of India Net Contribution moving to double digits (~5x of FY22) in FY25. Internationally, faster growth in MENA and South Africa helped in reducing dependence on Bangladesh to 42% vs 51% in FY22. Even in Bangladesh, revenue dependence on coconut oil has reduced to 58%.
- **Distribution:** In India, organized trade continues to gain traction where GT remains a critical channel for its core categories and in tier 2 and beyond markets. The company, under project SETU, has taken concerted efforts to revive GT's performance. The project is active in 11 states and focuses on rural outlet expansion on a pan-India level, underpinned by robust control frameworks. The initiative will also aid in better assortment in urban stores and drive premiumization. Internationally, Marico continues to deepen its presence across key markets—Bangladesh, Vietnam, Middle East, and Egypt, where it sees meaningful headroom for distribution-led growth.
- **Digital:** The company has consistently invested in digital and analytical capabilities across the value chain and core functions. Since launching in 2019, its digital transformation initiatives enabled data-led decisions by using AI/ML and real-time systems, driving a measurable impact in demand sensing, spend effectiveness, inventory optimization, and innovation via social listening. The company has embarked on a Next-gen ERP journey by implementing SAP S/4 under RISE (SaaS) across geographies.
- **Diversity:** Inclusion and diversity are central to Marico's organizational strategy, with a clear focus on three pillars—Gender, Persons with Disability, and Thought Diversity.

Management capability augmentation aiding growth agenda

The company has onboarded three professionals on the management team – Dr Shilpa Vora (Chief R&D officer) and Vrijesh Nagathan (Chief Information and Digital Technology officer) in Mar-22. In Mar-24, it onboarded Akash Banerji (Executive VP and Head, Digital transformation and Beauty and Styling Digital business).

Dr Shilpa aided innovation agenda at the company

The innovation funnel enhanced under Dr Shilpa, who joined Marico in Mar-22 after serving 24 years at Hindustan Unilever. Marico's focus has been on delivering high-impact, science-backed solutions that reflect local consumers' aspirations, traditions, and evolving lifestyles. The company launched 8 products in FY25.

- In **Beauty and personal category**, the 4 noteworthy launches were: a) *Parachute Advanced Baby Care Range* – Nurturing with Nature, Infused with the natural goodness of Virgin Coconut Oil, Almond Oil, and Vitamins E & F; b) *Set Wet* – Styling for the New-Age Man; c) *Livon Style Pro* – Breaking Ground Female Grooming Products, and d) *Herbs India* (MENA and Egypt) – Powered by Nature, Backed by Science.

Exhibit 1: Innovations in Beauty and Personal Care

Source: Company, Emkay Research


- In **Food**, the noteworthy innovations were: a) Oats and oat products - *Saffola Cuppa Oat*, b) Breakfast cereal – launched in three flavors: Kesar Crunch, Berry Crunch, and Choco Crunch, c) *Saffola Honey Gold* (100% pure honey sourced from Kashmir) and *Saffola Honey Active* (harvested from Sundarbans), and d) *True Elements*.

Exhibit 2: Product introductions in Food


Source: Company, Emkay Research

India: Rural demand recovery and steady urban in FY25

The India business delivered a growth of 14% YoY, aided by price interventions in core categories in response to sharp rises in input costs. The underlying volume growth stood at 5%. The operating margin for the India segment was 20.2% in FY25, down by 220bps YoY. Margin moderation was attributed to elevated copra and vegetable oil prices, although partially mitigated by pricing actions in key portfolios.

Exhibit 3: India revenue trend

Source: Company, Emkay Research

Exhibit 4: India revenue growth

Source: Company, Emkay Research

The management noted that the FMCG sector had demonstrated steady demand, underpinned by a gradual recovery in rural sentiment and stable urban consumption. Rural growth was aided by favorable rainfall, higher minimum support prices (MSPs), and continued government expenditure while urban consumption presented a more nuanced picture (with positive momentum in the upper-middle income and affluent segments and heightened retail and food inflation during most of the year, weighing on mass urban consumption). Moderation in retail and food inflation toward the end of FY25, coupled with forecasts of a healthy monsoon season, augurs well for FY26.

Efforts to address consumer needs across channels

Alternate channels such as Modern Trade and E-commerce continued to gain momentum. With quick commerce rapidly scaling up to ~3% of India business in FY25, the company is building assortment across categories to effectively capitalize on the potential of this channel. Additionally, GT remains stressed where the company is looking to revive growth under Project SETU, which is now active in 11 states. Under Project SETU, the company is looking to enhance its direct reach from 1mn to 1.5mn by FY27. This project is initiated to:

- Enhance in-store assortment,
- Optimize infrastructure, and
- Improve distributor ROI.

The thrust now is on rural outlet expansion on a pan-India basis.

Ky opportunities and trends in India business

In a consumption driven economy, per-capita FMCG consumption at USD49 is less than a quarter of regional peers' levels. This provides a growth runway to the company. The management sees key opportunities and trends shaping up the FMCG industry:

- **Youth redefining the FMCG playbook:** Millennials and Gen Z—projected to make up nearly 50% of India's population by 2030—are shaping the next wave of consumer trends. Their preferences are rooted in convenience, digital-first behavior, and wellness. They are research-driven, comparison-oriented, and demand transparency—prompting a surge in 'know before you buy' behavior.
- **Aspirations fuel consumption, aiding premiumization:** McKinsey projects India will be home to the world's third largest high-income household base by 2030. A burgeoning middle class now represents the largest segment of the population, as the low-income cohort shrinks and affluence rises. This shift is catalyzing greater consumer spending, driving demand for premium and aspiration-led products across categories such as personal care, home care, nutrition, and wellness.
- **D2C brands reshaping the FMCG ecosystem:** The traditional FMCG model—marked by time-consuming consumer research, broad-based product development, and reliance on fragmented distribution networks—is being redefined. The rise of a) digital technology, b) a more experimental consumer mindset, and c) an entrepreneurial start-up ecosystem has given birth to a new breed of FMCG players: Direct-to-Consumer (D2C) brands.
 - These brands leverage digital channels to go straight to the consumer, skipping intermediaries. With sharp value propositions, targeted digital marketing, and deep consumer insights, they've scaled rapidly. Their agility allows them to innovate faster, build emotional resonance, and form tight-knit communities of brand loyalists.
 - D2C brands are also masters of retention and re-engagement – often using social media, influencer tie-ups, and subscription models to maintain direct and repeat touchpoints with their consumers. As they continue to mature, many are exploring hybrid models and offline expansion, further strengthening their presence.
- **Rapid growth in e-commerce aided by quick commerce:** As per Nielsen, online FMCG sales could reach 11% by 2030, an eightfold increase from the current level. A big trend in this space is the rapid rise of Quick Commerce— a model that promises deliveries in minutes. Over two-thirds of all online grocery orders and nearly 10% of total e-retail spending in 2024 occurred via Q-commerce platforms. These platforms now include personal care, medicines, drinks, and snacks.
 - Bain & Company expects it to grow over 40% annually through 2030, driven by expansion into new categories, beyond metro cities, and growing consumer comfort with app-based instant shopping.
- **The New Digital India:** In the post-Covid world, digital transformation is no longer optional— it's central to FMCG competitiveness. Predictive analytics and machine learning now guide everything from product development to distribution strategy.

The company has overall outlet reach of 5.8mn.

- **Sustainability – a natural part of India’s consumer journey:** According to Bain & Company, while Indian consumers do consider sustainability, they take less conscious decisions and more of intuitive ones, shaped by culture and values.
- **Rural, a structural tailwind for FMCG:** The average rural FMCG basket size has surged ~60% between 2022 and 2024 (Kantar), with a clear shift toward premium products. Increasing internet access and smartphone adoption are enabling deeper engagement through e-commerce and digital marketing. With rural per capita income rising and the share of population remaining dominant (~65%), FMCG companies are well positioned to capture long-term value.


Parachute volumes to see recovery, on expected easing in copra

Parachute rigid pack sales represent 38% of domestic revenue.

The rigid pack portfolio strengthened its market leadership (gained 70bps of volume market share on a MAT basis), despite consumption titration and sharp price hikes in response to hyperinflationary trends in input costs. To address inflationary stress, brands implemented ml-age reduction in select packs during FY25. In FY25, the portfolio saw 13% revenue growth, with 2% volume growth. With expected easing in copra prices in FY26, the management expects a gradual recovery in volumes. With robust supply chain and execution agility, the management is confident about outperforming local players as the setting improves ahead.


Flanker Coconut Oil portfolio (including Nihar Naturals and Oil of Malabar) recorded mid-single digit volume growth in FY25. Overall, the volume market share of the Coconut Oil franchise was at 63%. Unbranded coconut oil market share remains at 25-30%, presenting an opportunity for branded offerings.

Exhibit 5: Parachute revenue (rigid pack)



Source: Company, Emkay Research

Exhibit 6: Parachute growth trend and expectations




Source: Company, Emkay Research

Edible oil volumes to improve with stability in RM prices

The company had to react with sharp price hikes in H2FY25, on sharp inflation in RM prices and duty imposition. Segmental revenue (19% of domestic revenue) grew 13% with low single-digit volume growth. The management’s strategic priority was to safeguard profitability threshold in this portfolio while maintaining stability in volumes. In FY26, on the back of easing in duty, the company has reacted with cuts in selling prices, thus aiding volumes.




Exhibit 7: Edible oil revenue



Source: Company, Emkay Research

Exhibit 8: Edible oil growth trend and expectations



Source: Company, Emkay Research



VAHO represents 19% of domestic revenue.


VAHO portfolio had a muted FY25; expected to have a robust FY26

Affected by aggressive competitive intensity, particularly at the bottom of the pyramid, VAHO portfolio had a muted FY25, with revenue declining 4% YoY. Mid-and-premium segments continued to perform relatively better. The franchise maintained its leadership position with 28% value market share, up 120bps YoY on MAT basis.

- *Nihar Shanti Amla* had a challenging year amid persistent irrational competition. The management is looking to turn around the franchise with focused interventions.
- *Parachute Advanced Jasmine* delivered a resilient performance, maintaining its momentum despite intensifying competition, and continued to gain market share during the year.
- With its refreshed damage repair proposition, *Hair & Care* continued to drive brand penetration.


The management is assured of marked improvement in growth in FY26, backed by a) focused interventions for the bottom-of-the-pyramid segment, b) consistent brand-building investments, and c) sharper brand activations. Its efforts are on driving growth in mid-and-premium segments; meanwhile, stabilizing the bottom-of-the-pyramid segment will lead to improved mix and steady uptick in value growth.

Exhibit 9: VAHO revenue



Source: Company, Emkay Research

Exhibit 10: VAHO growth trend and expectations



Source: Company, Emkay Research



Food revenue (11% of domestic revenue) at ~Rs9bn

The management's concerted efforts in diversification of revenue from food have been aiding in a healthy scale-up of the portfolio. In the last five years, the company has expanded revenue ~5x to Rs9bn (up 33% YoY in FY25) and aspires to expand the multiple to 8x by FY27, at 25% revenue CAGR. During the year, Saffola brands expanded into Muesli, Masala Millets, and Cuppa Oats. With focused efforts, the company has enhanced its portfolio gross


This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

margin by ~10ppt in the last couple of years. Over the medium term, the management is looking to gradually expand margins.

Saffola's product portfolio is designed to reinforce Marico's commitment to the No Nasties policy (no palm oil, maida, preservatives, artificial colors or flavors).


- *Saffola Oats* retained its position as the No 1 brand in the oats category, delivering healthy double-digit growth while continuing to gain volume market share.
- *Saffola Soya Chunks*, plant-based protein proposition, continued its strong trajectory and is on track to becoming a Rs1bn brand in the medium term.
- *Saffola Honey* continued to strengthen its presence, holding close to double-digit market share in Modern Trade and +20% market share in e-commerce.
- During the year, the brand relaunched its offering in the ready-to-eat snacks category with *Saffola Crunchiez Ragi Chips*.
- The brand also entered the fastest growing segment within breakfast cereals with *Saffola Muesli* in three exciting variants — Berry Crunch, Kesar Crunch, and Choco Crunch.
- The company has launched *Saffola Masala Millets* in two flavorful variants — Masala Delight and Tomato Delight.
- *True Elements* scaled up impressively in FY25, remaining steadfast in its commitment to innovation and clean nutrition.
- *Plix*, a plant-based brand in nutraceuticals and personal care, sustained its rapid growth trajectory in FY25. *Plix* holds the potential to scale up to Rs10bn revenue in the medium term.

Exhibit 11: Food portfolio revenue



Source: Company, Emkay Research

Exhibit 12: Food- contribution to domestic revenue



Source: Company, Emkay Research

'Sprinklr', Marico's social listening platform, serves as a key enabler in capturing the voice of customers across digital touchpoints. This enables the team to stay agile and responsive to consumer sentiment, preferences, and emerging trends.

Health and nutrition thrust aligns portfolio with consumer needs

Unlike other FMCG companies, Marico is building its food portfolio by aligning with nutritional needs of consumers. It has a Nutritional Profiling System, which benchmarks every food product against health and nutrition criteria, derived from scientific research and global best practices. This ensures that offerings align with international standards of sugar, sodium, fat, protein, fibre, and essential micronutrients.

The entire Saffola portfolio is based on stringent Health and Nutrition guidelines stated in Marico's Product Stewardship policy, with no palm oil, maida or artificial colors/flavors as the mandate for any food product of Marico.

To further enhance the health quotient, the company has worked on:

- **Sodium reduction:** Launched new variants with up to 20% reduced sodium content in key products such as Saffola Masala Oats, Saffola Masala Millets, and Saffola Crunchiez
- **Sugar reduction:** None of the products of the portfolio contain refined sugar.
- **Fortification and Functional Nutrition:** Saffola edible oil is enriched with vitamins A and D and contains natural form of vitamin E. Saffola Muesli is fortified with 8 essential micronutrients, including B complex vitamins, iron, and biotin. Saffola Multigrain Oats offers a goodness of oats plus multigrain, with a bundle of protein, fiber, and micronutrients.

This report is intended for internal use only. White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

- **Nutritive Ingredients Portfolio:** The company exclusively uses proven, health-supportive base ingredients such as oats, soya, millets, multi-source edible oils (MSEOs), nuts and seeds, and honey.

Premium personal care stood flat; digital-first expands


Premium personal care had flat sales YoY in FY25 with revenue at Rs3bn. However, digital brands had a strong scale-up. The management's focused attention on the digital-first portfolio has aided an annualized revenue run rate of Rs7.5bn, which is ahead of its initial targets. Seeing the path ahead, the management has revised up its expectations for FY27 to 2.5x of FY24 levels vs 2x earlier.

The digital-first portfolio comprises Beardo, Just Herbs, and the personal care segment of Plix, scaling up well ahead of aspirations.

- *Beardo* has scaled nearly 4x since FY21, reaching close to double-digit EBITDA margin. The brand posted +20% growth in FY25 and has the potential to reach the Rs5bn mark in the medium term.
- *Just Herbs* blends traditional Ayurvedic wisdom with modern science to offer beauty solutions that are safe, honest, and effective. In FY25, the brand crossed the Rs1bn revenue milestone, supported by portfolio expansion into natural makeup and pure fragrances.
- *Plix's* personal care portfolio is steadily gaining consumer traction and delivered single-digit EBITDA margin during the year.


With continued focus on profitability and scale, Marico aspires to deliver double-digit EBITDA margin across its digital-first portfolio by FY27.

Exhibit 13: Digital brands portfolio revenue



Source: Company, Emkay Research

Exhibit 14: Digital brands' contribution to domestic revenue



Source: Company, Emkay Research



The management considers its model as unique (since it has engineered a profitable and sustainable growth model, which does not rely on cash burns). Among the acquired digital brands, the company now has 2 distinct cohorts at different stages of their growth journey.

- The first cohort consists of *Beardo* and *Plix*, which are profitable at the EBITDA level and are on an accelerated growth path. The management expects these two brands to cross Rs10bn in combined ARR in FY26, with a clear focus on driving operating profitability with scale.

Exhibit 15: Digital brands portfolio

Source: Company, Emkay Research

Exhibit 16: Beardo – Profit and loss statement

(Rs mn)	FY20	FY21	FY22	FY23	FY24	FY25
Revenue from operations	796	634	949	1,066	1,732	2,142
growth		-20%	50%	12%	62%	24%
COGS	323	231	296	369	675	941
Gross profit	473	403	652	698	1,056	1,201
growth		-15%	62%	7%	51%	14%
gross margin	59%	64%	69%	65%	61%	56%
Employee costs	122	104	106	126	125	141
as a % of revenue	15%	16%	11%	12%	7%	7%
A&P spends	241	189	373	413	439	524
as a % of revenue	30%	30%	39%	39%	25%	24%
Other operating spends	76	162	178	228	420	340
as a % of revenue	10%	26%	19%	21%	24%	16%
EBITDA	33	(52)	(5)	(70)	72	196
growth		-256%	-91%	1415%	-204%	172%
EBITDA margin	4%	-8%	0%	-7%	4%	9%
Depreciation	4	6	6	8	11	19
EBIT	29	(57)	(11)	(78)	61	177
growth		-299%	-81%	619%	-178%	191%
Finance costs	0	2	2	9	13	10
Other income	7	8	7	3	1	7
PBT	36	(52)	(5)	(84)	48	174
growth		-245%	-90%	1462%	-158%	261%
Tax	(9)	(1)	13	23	(12)	(44)
PAT	27	(53)	8	(61)	36	130
growth		-296%	-114%	-912%	-158%	264%

Source: Company, Emkay Research

Exhibit 17: Satiya Nutraceuticals Private (Plix) – Profit and loss statement

	Standalone	Consolidated	
(Rs mn)	FY25	FY24	FY25
Contracted price	4,233	1,565	4,380
Less: Discounts	51	12	51
as a % of contracted price	1%	1%	1%
Revenue from operations	4,182	1,553	4,328
growth	188%		179%
COGS	1,160	419	1,148
Gross profit	3,022	1,134	3,180
Gross margin	72%	73%	73%
Employee costs	195	162	198
as a % of revenue	5%	10%	5%
A&P spends	1,916	687	1,942
as a % of revenue	46%	44%	45%
Other operating spends	812	427	963
as a % of revenue	19%	27%	22%
EBITDA	100	(142)	77
EBITDA margin	2%	-9%	2%
Depreciation	26	14	26
EBIT	74	(155)	51
Finance costs	6	2	6
Other income	29	31	35
PBT	96	(126)	80
Tax	-36	35	-32
PAT	60	(92)	48

Source: Company, Emkay Research

Exhibit 18: Key revenue streams for Plix

	FY25	FY24	FY25
Weight management	2,214	1,013	2,292
Personal care	1,940	502	2,009
Others	28	38	28
Revenue	4,182	1,553	4,328

Source: Company, Emkay Research

- The second cohort consists of *Just Herbs* and *True Elements*, though not yet at breakeven, and will focus on sustainable 20-25% growth and leveraging scale and synergy to achieve breakeven at the earliest over the next 18 to 24 months.

Exhibit 19: Apcos Natural – Just Herbs – Profit and loss statement

(Rs mn)	FY21	FY22	FY23	FY24	FY25
Revenue from operations	173	351	593	960	988
growth		103%	69%	62%	3%
COGS	26	73	161	238	265
Gross profit	146	278	432	722	723
growth		90%	55%	67%	0%
Gross margin	85%	79%	73%	75%	73%
Employee costs	21	43	66	96	131
as a % of revenue	12%	12%	11%	10%	13%
A&P spends	91	220	385	504	630
as a % of revenue	53%	63%	65%	53%	64%
Other operating spends	43	80	122	193	216
as a % of revenue	25%	23%	21%	20%	22%
EBITDA	(9)	(65)	(141)	(71)	(254)
growth		617%	117%	-50%	256%
EBITDA margin	-5%	-19%	-24%	-7%	-26%
Depreciation	6	7	8	10	13
EBIT	(16)	(72)	(149)	(81)	(267)
growth		364%	106%	-45%	228%
Finance costs	3	2	4	9	29
Other income	3	5	2	2	1
PBT	(15)	(70)	(152)	(88)	(294)
growth		353%	117%	-42%	233%
Tax	0	20	36	-19	-77
PAT	(15)	(50)	(115)	(70)	(217)

Source: Company, Emkay Research

Exhibit 20: Just Herbs revenue split

	FY23	FY24	FY25
Hair care	76	68	67
Skin care	104	86	74
Body care	24	31	
Make up	369	689	711
Fragrances	18	86	136
Others	1	1	
Total revenue	592	960	988

Source: Company, Emkay Research

Exhibit 21: HW Wellness Solutions – True Elements – Profit and loss statement

(Rs mn)	FY24	FY25
Contracted price	841	1,733
Less: Discounts	79	93
as a % of contracted price	9%	5%
Add: Others	2	0
Revenue from operations	764	1,644
growth	33%	115%
COGS	418	947
Gross profit	346.1	696.8
Gross margin	45%	42%
Employee costs	185	242
as a % of revenue	24%	15%
A&P spends	163	416
as a % of revenue	21%	25%
Other operating spends	205	273
as a % of revenue	27%	17%
EBITDA	(207)	(234)
EBITDA margin	-27%	-14%
Depreciation	27	34
EBIT	(234)	(268)
Finance costs	11	20
Other income	19	4
PBT	(225)	(284)
Tax	66	51
PAT	(159)	(233)

Source: Company, Emkay Research


The company is looking to drive significant operational synergies and leverage 1P data across its digital business to unlock further efficiencies. The management firmly believes that the company is on track to becoming one of the most successful digital FMCG companies in the country.

The combined revenue share of Food and Premium Personal Care in the India business stood at ~22% in FY25, representing a combined ARR of ~Rs20bn. The management is looking to continue to aggressively diversify through these portfolios, in line with its medium-term strategic priorities, and expects these to expand domestic revenue to ~25% by FY27. These new businesses continue to deliver higher gross margins compared to core categories, thereby bearing the potential of margin accretion as they scale further. The share of combined businesses in the India business net contribution rose to double digits, which is ~5x of FY22 levels. As a result of the evolving revenue mix, the company is building a structurally resilient India business with lower dependency on commodity-linked businesses.

International: Thrust on sustaining double-digit growth


Marico saw broad-based double-digit constant currency growth at ~14% in FY25. In rupee terms, growth was 8% YoY to Rs27.2bn (~25% of consolidated revenue). Bangladesh remained resilient with double-digit growth despite a tough environment. MENA and South Africa continued their strong growth trajectories, while Vietnam saw a relatively subdued year with mid-single-digit growth. Operating margin improved to 27.9% in FY25, up from 26.8% in the previous year, driven by premiumization of portfolios across markets and operating leverage from accelerated scale-up in MENA and South Africa.

Exhibit 22: International revenue trend



Source: Company, Emkay Research

Exhibit 23: International revenue growth



Source: Company, Emkay Research

Premium portfolios' share at 29%

The company made visible progress in premiumizing its portfolios across markets, with innovations and expansions into Premium Personal Care categories like shampoos, skincare, hair styling care (excluding hair oils), and baby care. These premium portfolios have grown at a disproportionately higher pace than the core portfolio over the last 4 years, with their revenue share reaching ~29% in FY25. The management noted that it will continue to invest aggressively toward diversifying the portfolio, expanding the total addressable market, and driving market-share gains in each of the markets.

Bangladesh (42% of international) saw 12% CC growth

Marico Bangladesh reported improved revenue growth in FY25, with constant currency revenue growing 12%. Adjusted for currency in rupee terms, revenue grew 7% YoY. Bangladesh continued to demonstrate visible resilience despite early operational headwinds, which eased in the latter half of the year. On the macro front, GDP growth in the country decelerated to 3.9% in FY25, from 4.2% in FY24 (Jun-24) and 5.8% in FY23. As per the Asian Development Bank, GDP growth is likely to improve to 5.1% in FY26.

The business has steadily reduced its dependence on the Coconut Oil portfolio, which now contributes ~60%. Leveraging its strong distribution backbone and learnings from India, the company remains focused on scaling up these growth engines and enhancing brand presence. The medium-term outlook for Bangladesh remains strong.

Exhibit 24: Marico Bangladesh – Profit and loss statement

(BDT mn)	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Turnover	7,349	7,066	6,916	7,815	8,768	9,796	11,307	13,032	14,136	14,524	16,309
growth	15.4%	-3.9%	-2.1%	13.0%	12.2%	11.7%	15.4%	15.3%	8.5%	2.7%	12.3%
Gross profit	3,306	3,181	3,206	3,585	4,295	5,672	6,668	7,071	7,325	8,425	9,711
Gross margin	45.0%	45.0%	46.4%	45.9%	49.0%	57.9%	59.0%	54.3%	51.8%	58.0%	59.5%
Marketing spends	943	639	538	580	774	1,148	1,358	1,254	989	1,015	1,190
as a % of sales	13%	9%	8%	7%	9%	12%	12%	10%	7%	7%	7%
EBITDA	1,930	2,020	2,060	2,430	2,860	3,509	4,445	4,860	5,369	6,423	7,370
OPM	26.3%	28.6%	29.8%	31.1%	32.6%	35.8%	39.3%	37.3%	38.0%	44.2%	45.2%
growth	9.0%	4.7%	2.0%	18.0%	17.7%	22.7%	26.7%	9.3%	10.5%	19.6%	14.7%
PBT	1,830	1,920	1,930	2,240	2,750	3,572	4,194	4,497	5,032	5,857	7,572
PBT margin	24.9%	27.2%	27.9%	28.7%	31.4%	36.5%	37.1%	34.5%	35.6%	40.3%	46.4%
growth	-2.7%	4.9%	0.5%	16.1%	22.8%	29.9%	17.4%	7.2%	11.9%	16.4%	29.3%
Tax	490	510	490	600	727	926	1,086	943	1,159	1,250	1,666
Tax rate	26.8%	26.6%	25.4%	26.8%	26.4%	25.9%	25.9%	21.0%	23.0%	21.3%	22.0%
PAT	1,340	1,410	1,440	1,640	2,023	2,646	3,109	3,554	3,872	4,606	5,906
PAT margin	18.2%	20.0%	20.8%	21.0%	23.1%	27.0%	27.5%	27.3%	27.4%	31.7%	36.2%
growth	-3.6%	5.2%	2.1%	13.9%	23.4%	30.8%	17.5%	14.3%	9.0%	19.0%	28.2%

Source: Company, Emkay Research

Exhibit 25: Marico Bangladesh's revenue by segment, growth, and contribution

(BDT mn)	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Parachute Coconut oil	5,958	5,630	5,346	5,809	6,054	6,363	6,989	8,035	8,576	8,593	9,464
VAHO	908	944	1,078	1,497	2,095	2,623	3,218	3,788	4,045	4,236	4,859
Color	121	81	68	48	56	58	60	45	45	40	36
Beauty and health						144	394	420	597	765	980
Baby care						93	167	228	277	336	388
Saffola - Edible Oil	18	13	26	51	107	97					
Parachute body lotion	17	70	62	70	51	0					
Others	326	327	337	340	407	417	479	515	596	554	584
Total	7,349	7,066	6,916	7,815	8,770	9,795	11,307	13,031	14,136	14,524	16,309
growth											
Parachute Coconut oil	7%	-6%	-5%	9%	4%	5%	10%	15%	7%	0%	10%
VAHO	38%	4%	14%	39%	40%	25%	23%	18%	7%	5%	15%
Color	8%	-33%	-16%	-29%	17%	4%	3%	-25%	0%	-12%	-10%
Beauty and health							174%	7%	42%	28%	28%
Baby care							80%	37%	21%	21%	15%
Saffola - Edible Oil	176%	-25%	92%	97%	110%	-9%					
Parachute body lotion		314%	-11%	13%	-27%						
Others	992%	0%	3%	1%	20%	2%	15%	8%	16%	-7%	5%
Total	15%	-4%	-2%	13%	12%	12%	15%	15%	8%	3%	12%
Contribution											
Parachute Coconut oil	81%	80%	77%	74%	69%	65%	62%	62%	61%	59%	58%
VAHO	12%	13%	16%	19%	24%	27%	28%	29%	29%	29%	30%
Color	2%	1%	1%	1%	1%	1%	1%	0%	0%	0%	0%
Beauty and health							1%	3%	4%	5%	6%
Baby care							1%	1%	2%	2%	2%
Saffola - Edible Oil	0%	0%	0%	1%	1%	1%					
Parachute body lotion	0%	1%	1%	1%	1%						
Others	4%	5%	5%	4%	5%	4%	4%	4%	4%	4%	4%
Total	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%

Source: Company, Emkay Research

Exhibit 26: Bangladesh portfolio

Source: Company, Emkay Research

Vietnam (20% of international) had a muted show in FY25

The company registered 4% constant currency growth in FY25, impacted by transient sluggishness in core categories. The business has seen strong traction in the shower gel segment, while Purité de Prôvence and Ôliv strengthened presence in the female personal care segment. GDP growth remained healthy at 7.1% for CY24 vs 5.1% in CY23. For CY25 and CY26, the Asian Development Bank projects GDP growth of 6.6% and 6.5%, respectively. Vietnam government had set a target of 8% GDP growth for CY25 and double-digit growth in the following year.

Exhibit 27: Vietnam product portfolio

Source: Company, Emkay Research

MENA region (~18% of international) saw a strong FY25

The MENA region posted constant currency growth of 36% in FY25, led by strong traction across markets. The Middle East and Egypt businesses grew 26% and 73%, respectively, in constant currency terms, driven by well-rounded performances across portfolios and successful product launches in both geographies.

Exhibit 28: Vietnam product portfolio

Source: Company, Emkay Research

South Africa (9% of international) had a healthy show

South Africa business delivered constant currency growth of 19% in FY25, led by strong performances in the Health Care and Hair Care segments. South Africa's economy grew by 0.6% in 2024, and the National Treasury expects medium-term GDP growth to average at 1.6% over 2025-27.

New Country Development and Exports (~9% of international)

The New Country Development and Exports segment grew 16% in FY25. The company continues to remain optimistic about the long-term prospects of this business as it incubates new geographies, to broaden its global footprint.

Outlook: Strengthening the growth construct

In India, the company expects to gradually improve growth trends in core categories on the back of moderating trends in retail and food inflation as well as the promise of a healthy monsoon season. This will be further aided by ongoing initiatives to support select General Trade (GT) channel partners and transformative expansion in the direct reach footprint under Project SETU. The company also continues to draw confidence from healthy offtakes, penetration, and market share gains in key portfolios. The management asserted that it would continue to focus on driving differential growth in urban-centric and premium portfolios through the organized retail and e-commerce channels. Therefore, it expects to deliver consistent and competitive growth in the medium term through a much sharper and targeted portfolio and SKU strategy in each channel.

With the strengthening growth construct of the business, the management maintains its aspiration to deliver double-digit revenue growth in the medium term through:

- Consistent outperformance vis-à-vis the category and market-share gains in India's core portfolios;
- Accelerated growth in the Food and Premium Personal Care in India, and
- Double-digit constant currency growth in the international business.


The company also expects operating margin to inch up over the medium term, with leverage benefits as well as premiumization of portfolios across India and international businesses.

Visible shift in India revenue construct with food and digital brands


Sustained investment toward accelerated scale-up of Food and Premium Personal Care portfolios enabled differential growth outcomes amid relatively slower demand in mass consumption-led franchises over the past few quarters. As discussed above, evolved food and digital brand business is likely to see steady expansion in contribution to 25% by FY27.

- Food clocked revenue of Rs9bn in FY25, which is a 5x scale-up since FY20. Here, the management has an aspiration to raise revenue over 25% CAGR. The company aspires for revenue of Rs14bn in FY27, which is 8x of FY20 revenue. The company saw structural gross margin expansion of ~100bps in Food over FY24-25.
- The digital-first brands clocked an annual revenue rate of Rs7.5bn on exit basis in FY25 which was better than the company's aspiration. By FY27, the management expects revenue from digital brands to scale to 2.5x ARR of FY24 (Rs4.5bn then). In this portfolio, Berdo and Plix clocked 9% and 2% EBITDA margins, respectively, while the rest of the portfolio saw negative margins. The management aspires for double-digit EBITDA margin for the portfolio by FY27.


Exhibit 29: Food, premium personal care, and digital brands revenue contribution in India



Source: Company, Emkay Research

Exhibit 30: Estimated food revenue breakdown

Source: Company, Emkay Research

Exhibit 31: Estimated digital brands revenue breakdown

Source: Company, Emkay Research

The company has seen rapid scale-up of these portfolios, accompanied by significant improvement in profitability, resulting in their share of India's Net Contribution (NC; calculated as revenue adjusted for all variable costs and marketing spends) moving to double digits (~5x of FY22 levels).

Exhibit 32: Snapshot of digital brand performance in FY25

(Rs mn)	Beardo	Plix	Just Herbs	True Elements	Combined
Revenue	2,142	4,328	988	1,644	9,102
Growth	24%	179%	3%	115%	82%
EBITDA	196	77	(254)	(234)	(214)
Growth	172%	NM	256%	13%	NM
EBITDA margin	9%	2%	-26%	-14%	-2%
Adj PAT	130	48	(217)	(233)	(272)
Growth	264%	NM	211%	47%	NM

Source: Company, Emkay Research; Note: NM means Not Meaningful (given losses in base)

Visible strides toward premiumization in international business

The company has made visible strides toward premiumization of portfolios across international markets through innovation and expansion into premium personal care categories like shampoos, skin care, hair styling/care (ex-hair oils), and baby care.

These portfolios have scaled at a CAGR of 24% over FY21-25. As a result, the revenue share in the international business rose to ~29% in FY25, from ~20% in FY21. In this portfolio, the company aspires for growth of more than 25% in the medium term. Marico will continue to invest aggressively in diversifying its portfolio, expanding the total addressable market, and driving market-share gains in each of the markets.

Aspiring for double-digit constant currency growth internationally

Over the medium term, the company aims to maintain double-digit constant currency growth momentum in the international business. The company is also open for inorganic opportunities that offer a meaningful chance to consolidate its competitive position in existing categories, expand the total addressable market in existing geographies or access markets of interest, thereby adding visible levers to drive long-term value creation.

Better earnings to aid returns and cash creation

Marico's strategy is focused on double-digit profitable growth. With no major capex needs in the business, the company is well placed to see steady return ratio expansions and healthy cash generation. However, during FY25, the company had a muted show, as increased working capital needs affected cash generation. On the back of 10% increase in earnings, its dividend increased 11%, however, the payout remains steady at 83%.

Working capital needs stretched on lower payable days

The company has maintained its net working capital requirement of 47 days in its standalone business; however, it has reduced inventory by 10 days to 39 on the back of its focus on supply chain efficiency amid inflationary copra prices. Its payable days have been reduced by 11 days to 37, which, in our view, would support farmers and assure supplies of (inflationary) copra. In the subsidiaries business, the company has seen increase in working capital requirement by 10 days YoY to 29. Payable days have shrunk by 29 days and receivable days increased by 10 days to 38. Meanwhile, focused interventions have aided a reduction in inventory days by 7 days YoY to 48. Overall, on a consolidated level, working capital requirement increased by 7 days YoY to 39. Inventory days reduced by 9 days (to 42), while payable days shrunk by 14 days (to 46).

Exhibit 33: Working capital requirements in the business


	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Consolidated								
Revenue	63,220	73,340	73,150	80,480	95,120	97,640	96,530	108,310
Inventory	15,110	14,110	13,800	11,260	14,120	12,250	13,360	12,350
Receivables	3,400	5,170	5,390	3,880	6,520	10,150	10,690	12,710
Payables	8,220	9,440	9,780	11,340	13,440	14,520	15,810	13,630
Inventory days	87	70	69	51	54	46	51	42
Receivable days	20	26	27	18	25	38	40	43
Payable days	47	47	49	51	52	54	60	46
Net working capital	59	49	47	17	28	29	31	39
Standalone								
Revenue	51,810	59,710	58,530	63,370	75,000	74,780	70,020	75,810
Contribution	82%	81%	80%	79%	79%	77%	73%	70%
Inventory	13,130	12,340	11,650	8,730	10,930	8,950	9,360	8,040
Receivables	2,880	4,300	4,650	3,100	5,550	8,380	8,700	9,350
Payables	5,870	7,150	7,090	8,420	10,000	10,060	9,130	7,670
Inventory days	93	75	73	50	53	44	49	39
Receivable days	20	26	29	18	27	41	45	45
Payable days	41	44	44	48	49	49	48	37
Net working capital	71	58	57	20	32	35	47	47
Subsidiaries								
Revenue	11,410	13,630	14,620	17,110	20,120	22,860	26,510	32,500
Contribution	18%	19%	20%	21%	21%	23%	27%	30%
Inventory	1,980	1,770	2,150	2,530	3,190	3,300	4,000	4,310
Receivables	520	870	740	780	970	1,770	1,990	3,360
Payables	2,350	2,290	2,690	2,920	3,440	4,460	6,680	5,960
Inventory days	63	47	54	54	58	53	55	48
Receivable days	17	23	18	17	18	28	27	38
Payable days	75	61	67	62	62	71	92	67
Net working capital	5	9	5	8	13	10	-10	19

Source: Company, Emkay Research

Enhanced profitability largely shared with shareholders


Marico has clocked low double-digit earnings CAGR in the last couple of years which we believe would sustain over the medium term. Its actions to enhance the portfolio mix, with high gross margin offering, are likely to help extend the double-digit earnings growth momentum. In our view, with earnings improving, the company is likely to sustain over 80% dividend payout, which is a decent reward to shareholders.

Exhibit 34: Revenue and earnings growth trends



Source: Company, Emkay Research

Exhibit 35: Dividend payout




Source: Company, Emkay Research

Return profile continues to expand

With limited capex needs in the business, the company has been generous with its dividend payouts. Healthy operating cash generation is sufficient to fund any expansionary needs. Return on equity expanded by 290bps YoY to 41.7%, while return on capital (pre-tax) employed grew 175bps YoY to 45.8%. Adjusted for liquidity, ROIC expanded by 9ppt YoY to 66%.

Exhibit 36: Return ratios continue to see expansion



Source: Company, Emkay Research

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a


Exhibit 37: Du Pont analysis

	FY13	FY14	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Fixed asset turn (x)	3.6	3.5	5.9	9.4	8.1	7.6	7.9	6.9	6.7	6.8	5.9	4.6	4.3
Net profit margin (%)	8.6	10.8	10.2	12.0	14.0	13.1	12.9	14.7	14.8	13.3	13.5	15.6	15.3
Fixed assets/ equity (x)	0.8	0.8	0.6	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.5	0.5	0.6
ROE (%)	25.4	30.2	36.7	37.9	38.2	34.0	34.1	35.6	37.9	38.3	37.0	39.4	42.5


Source: Company, Emkay Research

OCF stood flat, while lower capex aided FCF generation


In FY25, Marico's earnings grew 10% YoY, while operating cash flow stood flat YoY, given higher working capital need in the business. Capex spending in the year stood at Rs1.2bn, down from Rs2.4bn in FY24. This aided 10% YoY expansion in free cash generation in the business. We see better earnings ahead.

Exhibit 38: Cash generation steady YoY


Source: Company, Emkay Research

Exhibit 39: OCF/share


Source: Company, Emkay Research

Exhibit 40: FCF/share

Source: Company, Emkay Research

Exhibit 41: EBITDA to FCF conversion

Source: Company, Emkay Research


Exhibit 42: Earnings to free cash conversion has been healthy

Source: Company, Emkay Research

Valuation to factor in enhanced execution


On the back of relatively better execution, Marico has been trading between its mean and +1SD 5Y average valuations. As noted in our recent note: **Inflationary copra prices, a near-term concern ([link](#))**, amid a steady surge in copra prices, the stock has seen some de-rating over the last fortnight. However, copra prices have arrested their inflationary trend and are seeing moderate deflation. If the trend continues, we expect the stock to re-rate to +1SD.

Exhibit 43: One year forward P/E (on consensus)




Source: Bloomberg, Emkay Research

Exhibit 44: Copra price trend



Source: Company, Emkay Research

Exhibit 45: Coconut oil price trend



Source: Company, Emkay Research

We maintain BUY with Jun-26E TP of Rs810, on 50x P/E. We see improved execution ahead helping the company in driving growth and margins. The new portfolio in India and internationally is aligning with consumer needs, enhancing longevity of growth. In India (75% of revenue), the new-age portfolio in food and digital brands represents 22% of revenue, while internationally, the premium portfolio represents 29% of sales. Put together, the company has 1/4th revenue here and is looking to drive faster growth ahead. We see execution in this portfolio (where core can drive high single-digit growth) being key for the 15% CAGR aspiration ahead.

Exhibit 46: Key assumptions

	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Profit and loss account								
Sales growth	10%	18%	3%	-1%	12%	13%	9%	10%
EBITDA growth	8%	6%	7%	12%	6%	11%	17%	10%
Earnings growth	10%	6%	6%	14%	10%	9%	17%	10%
Gross margin	47%	43%	45%	51%	50%	50%	52%	52%
A&P spends as a % of sales	9%	8%	9%	10%	10%	11%	11%	11%
EBITDA margin	20%	18%	19%	21%	20%	19%	21%	21%
Adj EPS (Rs)	9.0	9.6	10.1	11.5	12.6	13.7	16.0	17.6
DPS (Rs)	7.5	9.3	4.5	9.5	10.5	11.5	13.5	15.0
Balance sheet								
Avg. ROCE	42%	43%	42%	44%	46%	49%	54%	55%
Avg. RoE	37%	37%	36%	39%	42%	43%	47%	48%
Inventory days	51	54	46	51	42	42	42	42
Receivable days	18	25	38	40	43	43	43	44
Payable days	51	52	54	60	46	50	50	50

Source: Bloomberg, Emkay Research

Exhibit 47: Emkay estimates vs consensus

(Rs mn)	Emkay estimates			Consensus			Emkay estimate vs consensus		
	FY26E	FY27E	FY28E	FY26	FY27	FY28	FY26E	FY27E	FY28E
Revenue	122,640	133,780	147,024	119,588	131,716	142,445	3%	2%	3%
Growth	13.3%	9.1%	9.9%	10.5%	10.1%	8.1%			
EBITDA	23,737	27,876	30,704	24,158	27,410	29,195	-2%	2%	5%
Growth	11.0%	17.4%	10.1%	12.9%	13.5%	6.5%			
EBITDA margin	19.4%	20.8%	20.9%	20.2%	20.8%	20.5%			
Adj PAT	17,717	20,698	22,714	18,201	20,663	22,782	-3%	0%	0%
Growth	8.8%	16.8%	9.7%	11.7%	13.5%	10.3%			
EPS	13.73	16.05	17.61	14.08	15.98	17.61	-2%	0%	0%

Source: Bloomberg, Emkay Research

Marico: Consolidated Financials and Valuations

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	96,530	108,310	122,640	133,780	147,024
Revenue growth (%)	(1.1)	12.2	13.2	9.1	9.9
EBITDA	20,260	21,390	23,737	27,876	30,704
EBITDA growth (%)	11.9	5.6	11.0	17.4	10.1
Depreciation & Amortization	1,580	1,780	1,900	2,050	2,200
EBIT	18,680	19,610	21,837	25,826	28,504
EBIT growth (%)	12.9	5.0	11.4	18.3	10.4
Other operating income	800	980	1,049	1,122	1,201
Other income	1,420	2,080	1,850	2,100	2,500
Financial expense	730	530	525	525	525
PBT	19,370	21,160	23,162	27,401	30,479
Extraordinary items	0	0	0	0	0
Taxes	4,350	4,580	5,096	6,302	7,315
Minority interest	(210)	(290)	(350)	(400)	(450)
Income from JV/Associates	-	-	-	-	-
Reported PAT	14,810	16,290	17,717	20,698	22,714
PAT growth (%)	13.7	10.0	8.8	16.8	9.7
Adjusted PAT	14,810	16,290	17,717	20,698	22,714
Diluted EPS (Rs)	11.5	12.6	13.7	16.0	17.6
Diluted EPS growth (%)	13.7	10.0	8.8	16.8	9.7
DPS (Rs)	9.5	3.5	11.5	13.5	15.0
Dividend payout (%)	83.0	27.8	83.7	84.1	85.2
EBITDA margin (%)	21.0	19.7	19.4	20.8	20.9
EBIT margin (%)	19.4	18.1	17.8	19.3	19.4
Effective tax rate (%)	22.5	21.6	22.0	23.0	24.0
NOPLAT (pre-IndAS)	14,485	15,365	17,033	19,886	21,663
Shares outstanding (mn)	1,290	1,290	1,290	1,290	1,290

Source: Company, Emkay Research

Balance Sheet					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	1,290	1,290	1,290	1,290	1,290
Reserves & Surplus	37,030	38,460	41,342	44,625	47,989
Net worth	38,320	39,750	42,632	45,915	49,279
Minority interests	3,370	2,910	3,260	3,660	4,110
Non-current liab. & prov.	2,790	2,480	2,604	2,734	2,871
Total debt	5,290	13,630	14,312	15,027	15,778
Total liabilities & equity	49,770	58,770	62,807	67,336	72,038
Net tangible fixed assets	-	-	-	-	-
Net intangible assets	-	-	-	-	-
Net ROU assets	2,090	2,300	2,415	2,536	2,663
Capital WIP	440	400	500	500	500
Goodwill	8,630	8,570	9,695	9,695	9,695
Investments [JV/Associates]	3,430	2,150	2,650	3,150	3,650
Cash & equivalents	12,020	21,520	23,896	26,824	29,720
Current assets (ex-cash)	28,730	29,940	33,436	36,266	39,997
Current Liab. & Prov.	24,440	24,610	27,956	29,849	32,299
NWC (ex-cash)	4,290	5,330	5,480	6,417	7,697
Total assets	49,770	58,770	62,807	67,336	72,038
Net debt	(6,730)	(7,890)	(9,585)	(11,797)	(13,941)
Capital employed	49,770	58,770	62,807	67,336	72,038
Invested capital	29,440	30,610	31,467	32,353	33,434
BVPS (Rs)	29.7	30.8	33.0	35.6	38.2
Net Debt/Equity (x)	(0.2)	(0.2)	(0.2)	(0.3)	(0.3)
Net Debt/EBITDA (x)	(0.3)	(0.4)	(0.4)	(0.4)	(0.5)
Interest coverage (x)	27.5	40.9	45.1	53.2	59.1
RoCE (%)	44.5	42.0	40.7	44.8	46.4

Source: Company, Emkay Research

Cash flows					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	17,950	19,080	21,312	25,301	27,979
Others (non-cash items)	(110)	(580)	(510)	(510)	(109)
Taxes paid	(3,510)	(3,690)	(3,780)	(4,840)	(5,096)
Change in NWC	(1,220)	(1,350)	(26)	(806)	(1,144)
Operating cash flow	14,360	14,420	19,133	21,268	22,521
Capital expenditure	(2,380)	(1,870)	(2,706)	(2,000)	(2,000)
Acquisition of business	1,750	1,280	(500)	(500)	(500)
Interest & dividend income	-	-	-	-	-
Investing cash flow	1,760	(6,210)	(2,356)	(1,400)	(1,000)
Equity raised/(repaid)	340	0	0	0	0
Debt raised/(repaid)	(910)	(50)	(40)	0	250
Payment of lease liabilities	(340)	(210)	(115)	(121)	(127)
Interest paid	(540)	(510)	(525)	(525)	(525)
Dividend paid (incl tax)	(12,290)	(4,530)	(14,835)	(17,415)	(19,350)
Others	(1,680)	(1,190)	115	121	127
Financing cash flow	(15,420)	(6,490)	(15,400)	(17,940)	(19,625)
Net chg in Cash	700	1,720	1,376	1,928	1,896
OCF	14,360	14,420	19,133	21,268	22,521
Adj. OCF (w/o NWC chg.)	15,580	15,770	19,159	22,074	23,665
FCFF	11,980	12,550	16,426	19,268	20,521
FCFE	11,250	12,020	15,901	18,743	19,996
OCF/EBITDA (%)	70.9	67.4	80.6	76.3	73.3
FCFE/PAT (%)	76.0	73.8	89.8	90.6	88.0
FCFF/NOPLAT (%)	82.7	81.7	96.4	96.9	94.7

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E March	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	61.8	56.2	51.7	44.2	40.3
EV/CE(x)	19.4	16.2	15.1	14.1	13.1
P/B (x)	23.9	23.0	20.9	18.6	17.0
EV/Sales (x)	9.5	8.5	7.5	6.9	6.2
EV/EBITDA (x)	44.9	42.5	38.3	32.6	29.6
EV/EBIT(x)	48.7	46.4	41.6	35.2	31.9
EV/IC (x)	30.9	29.7	28.9	28.1	27.2
FCFF yield (%)	1.3	1.4	1.8	2.1	2.3
FCFE yield (%)	1.2	1.3	1.6	2.0	2.2
Dividend yield (%)	1.3	0.5	1.5	1.7	2.0
DuPont-RoE split					
Net profit margin (%)	15.3	15.0	14.4	15.5	15.4
Total asset turnover (x)	2.1	2.1	2.1	2.1	2.2
Assets/Equity (x)	1.2	1.3	1.4	1.4	1.4
RoE (%)	38.8	41.7	43.0	46.8	47.7
DuPont-RoIC					
NOPLAT margin (%)	15.0	14.2	13.9	14.9	14.7
IC turnover (x)	3.7	3.6	4.0	4.2	4.5
RoIC (%)	55.5	51.2	54.9	62.3	65.9
Operating metrics					
Core NWC days	16.2	18.0	16.3	17.5	19.1
Total NWC days	16.2	18.0	16.3	17.5	19.1
Fixed asset turnover	3.3	3.2	3.4	3.5	3.7
Opex-to-revenue (%)	29.8	30.5	30.6	30.7	30.6


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
17-Jul-25	733	810	Buy	Nitin Gupta
05-Jul-25	729	810	Buy	Nitin Gupta
30-Jun-25	722	810	Buy	Nitin Gupta
24-Jun-25	704	810	Buy	Nitin Gupta
04-May-25	698	810	Buy	Nitin Gupta
24-Apr-25	713	700	Add	Nitin Gupta
03-Apr-25	661	700	Add	Nitin Gupta
17-Mar-25	608	700	Add	Nitin Gupta
26-Feb-25	622	700	Add	Nitin Gupta
18-Feb-25	626	700	Add	Nitin Gupta
02-Feb-25	694	700	Add	Nitin Gupta
31-Jan-25	671	700	Add	Nitin Gupta
03-Jan-25	661	700	Add	Nitin Gupta
30-Oct-24	651	700	Add	Nitin Gupta
02-Oct-24	694	775	Add	Nitin Gupta
26-Sep-24	694	775	Add	Nitin Gupta
05-Aug-24	672	700	Reduce	Nitin Gupta
05-Aug-24	672	700	Reduce	Nitin Gupta
06-Jul-24	615	630	Reduce	Nitin Gupta
04-Jul-24	608	630	Reduce	Nitin Gupta
26-Jun-24	613	600	Add	Nitin Gupta
04-Jun-24	615	600	Add	Nitin Gupta
13-May-24	595	600	Add	Nitin Gupta
08-May-24	596	600	Add	Nitin Gupta
07-May-24	584	600	Add	Nitin Gupta
15-Apr-24	509	570	Add	Nitin Gupta
05-Apr-24	510	570	Add	Nitin Gupta
14-Mar-24	506	540	Reduce	Nitin Gupta
30-Jan-24	523	540	Reduce	Nitin Gupta
23-Jan-24	521	570	Reduce	Nitin Gupta
07-Jan-24	546	570	Reduce	Nitin Gupta
12-Dec-23	540	560	Reduce	Nitin Gupta
30-Nov-23	539	560	Reduce	Nitin Gupta
24-Nov-23	524	560	Hold	Nitin Gupta
30-Oct-23	532	560	Hold	Nitin Gupta
20-Oct-23	542	585	Hold	Nitin Gupta
04-Oct-23	571	585	Hold	Nitin Gupta
03-Oct-23	576	585	Hold	Nitin Gupta
28-Aug-23	558	565	Hold	Nitin Gupta
15-Aug-23	568	565	Hold	Nitin Gupta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of August 03, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of August 03, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 03, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.